Adalimumab
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
Adalimumab: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Adalimumab is a TNF-alpha blocking antibody, widely used for rheumatoid arthritis and other inflammatory diseases. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, but the supporting evidence is thin: 0 relevant clinical trials (5 retrieved, all unrelated to vasculitis efficacy) and 20 publications, most of them case reports and adverse-event reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis and other inflammatory conditions (per public labeling; the input data lists no approved indication text) |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (listed as BLAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. Based on known information, adalimumab is a fully human monoclonal antibody that neutralizes TNF-alpha. Its efficacy in rheumatoid arthritis and related inflammatory diseases is established, and mechanistically it may be applicable to rheumatoid vasculitis.
Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis. TNF-alpha drives the systemic inflammation of rheumatoid arthritis, so TNF blockade is biologically plausible here.
The evidence is much weaker than the mechanism, and it points in both directions:
- Possible benefit: a systematic review of biologic therapy in rheumatoid vasculitis (2021) and a case report of digital vasculitis that responded well to adalimumab.
- Possible worsening: one case report describes an acute pulmonary hypertension crisis after adalimumab dose reduction in rheumatoid vasculitis.
- Possible harm: several reports and cohorts describe paradoxical vasculitis-like or lupus-like events under TNF inhibitors, including adalimumab.
The high model score is therefore a hypothesis, not a confirmed treatment effect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Immunosuppressant hold duration before shoulder arthroplasty in rheumatology patients; not a vasculitis efficacy study |
| NCT05111743 | N/A | Completed | 9,261 | Real-world brolucizumab study in wet AMD; unrelated drug and disease |
| NCT05696106 | N/A | Unknown | 750,000 | Risk of new immune-mediated inflammatory diseases under biologics; a safety and epidemiology signal only |
| NCT02590562 | N/A | Completed | 808 | Cross-sectional biologic DMARD treatment patterns in RA in China; no vasculitis outcome |
| NCT01579006 | N/A | Completed | 184 | Non-interventional tocilizumab study in RA; no vasculitis outcome |
All five trials were graded C for relevance. None tests adalimumab for rheumatoid vasculitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic review | Clin Rheumatol | PRISMA-based review of biologic drugs in rheumatoid vasculitis, a severe extra-articular manifestation of RA |
| 18799049 | 2008 | Systematic review | Clin Exp Rheumatol | Compares vasculitis occurring during anti-TNF treatment versus not, in RA patients (2,707 patients, 18 vasculitis cases) |
| 28123776 | 2017 | Cohort / pharmacovigilance | RMD Open | Drug-specific risk of lupus-like and vasculitis-like events in RA patients on TNF inhibitors versus non-biologic DMARDs (BSRBR-RA) |
| 25133007 | 2014 | Case report | Case Rep Rheumatol | Digital vasculitis in a patient with RA responded well to adalimumab |
| 30773522 | 2019 | Case report | Intern Med | Acute pulmonary hypertension crisis eight months after adalimumab reduction in rheumatoid vasculitis |
| 36418100 | 2023 | Case report | Intern Med | ANCA-associated nephritis arising during abatacept and adalimumab for RA; attenuated by tocilizumab |
| 28719435 | 2018 | Case report (adverse event) | Am J Dermatopathol | Leukocytoclastic vasculitis after starting adalimumab for RA |
| 19482531 | 2009 | Case report | Nephrol Ther | ANCA-associated necrotizing glomerulonephritis in a patient treated with adalimumab for RA |
| 23559388 | 2013 | Case report and review | Clin Rheumatol | First reported adalimumab-associated antiphospholipid syndrome; reviews adalimumab-induced vasculitis |
| 24854356 | 2014 | Cohort | Ann Rheum Dis | Routine ANA testing to predict biologic-induced lupus and vasculitis in RA |
US Market Information
The input lists 20 authorizations; the main ones are shown below. No approved indication text is available for any of them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA761059 | Hadlima | Solution | Organon LLC |
| BLA761024 | AMJEVITA | Injection | Amgen, Inc |
| BLA761024 | AMJEVITA | Injection | Nuvaila Limited |
| BLA761071 | Adalimumab | Injection, solution | Sandoz Inc |
| BLA761071 | HYRIMOZ | Injection, solution | Cordavis Limited |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is mechanistically plausible, but no trial tests adalimumab for rheumatoid vasculitis. The literature is mostly case reports, with signals both for benefit and for paradoxical vasculitis. Package insert warnings are also missing, which blocks safety screening.
To proceed, the following is needed:
- FDA package insert warnings and contraindications
- Mechanism of action and original indications, both missing from the input
- Adalimumab-specific efficacy data in rheumatoid vasculitis, ideally a prospective study, since the systematic review covers biologics in general
- A risk assessment of paradoxical vasculitis-like and lupus-like events under adalimumab
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.